Fentanyl
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
- Fentanyl
- Fentanyl: From Unspecified Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis
Fentanyl: From Unspecified Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Fentanyl (DrugBank DB00813) has no original indication or mechanism-of-action data on file in this evidence pack. The TxGNN model predicts potential efficacy for Nephrogenic Syndrome of Inappropriate Antidiuresis, but this is currently supported by 0 clinical trials and 0 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (data gap) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 99.46% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature identified) |
| Market Status | Not marketed (0 licenses on file) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for fentanyl in this evidence pack, and no original approved indication was returned by the data pipeline (see Data Gaps DG001/DG002). Without a documented MOA or original indication to anchor a mechanistic comparison, it is not possible to assess whether the biological rationale for a link between fentanyl and nephrogenic syndrome of inappropriate antidiuresis is plausible.
The TxGNN score alone (99.46%) reflects the model’s internal ranking confidence but is not corroborated by any external evidence (clinical trials, literature, or regulatory precedent) in this evidence pack. This prediction should be treated as hypothesis-generating only until mechanism and indication data are filled in.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No approved authorizations on file (0 licenses; market status: not marketed)
Safety Considerations
Please refer to the package insert for safety information.
Note: Warnings, contraindications, and drug interaction data are marked as a Blocking data gap (DG001) — TFDA label warnings/contraindications have not yet been retrieved, which prevents this candidate from entering the S1 safety pre-screening stage.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication has zero supporting clinical trials or literature (L5, model prediction only), and the original indication, mechanism of action, and TFDA safety label data are all missing — including a Blocking-severity gap (DG001) that prevents safety pre-screening. There is currently no basis to advance this candidate.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001, Blocking) — required before any safety pre-screening
- Mechanism of action data via DrugBank API (DG002)
- Documentation of fentanyl’s original approved indication(s)
- Targeted clinical trial and literature search for fentanyl in nephrogenic syndrome of inappropriate antidiuresis, given current query results returned zero hits
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.